Kt Corporation ADR Aktie
Finanztrends
Deine Einschätzung
Kt Corporation ADR Aktie
Leichte Verluste bei der Kt Corporation ADR Aktie heute, ein Rückgang um -0,63 %.
Was spricht für und gegen Kt Corporation ADR in den nächsten Jahren?
Pro
?
M****
?
L*********** I********** f** d** n******* J****
?
A****************
Kontra
?
U****************
?
M************
?
W******* i* V********
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Kt Corporation ADR im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Kt Corporation ADR | -0,63 % | 0,64 % | 0,64 % | -7,06 % | 0,00 % | 41,07 % | 23,44 % |
| Freenet AG | 0,00 % | -0,83 % | 0,17 % | -15,10 % | -19,19 % | 9,26 % | 18,37 % |
| Philippine Long Distance Telephone Company ADR | -1,18 % | -0,60 % | 3,73 % | -14,36 % | -7,22 % | -19,71 % | -16,50 % |
| Telekom Austria AG | 0,79 % | 0,00 % | 0,60 % | 8,04 % | 12,25 % | 50,22 % | 32,28 % |
Kommentare
News
Kymera Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Kymera Therapeutics, Inc.? Here are five stocks we like better.
- KT-621 atopic dermatitis trial enrollment is complete about six months ahead of schedule, with top-line
Kymera's CEO Sold $6 Million in Stock After a 170% Run
Chief Executive Officer Nello Mainolfi sold 50,000 shares of Kymera Therapeutics (NASDAQ:KYMR) on July 7, 2026, for total proceeds of about $6.0 million, according to an SEC Form 4 filing.
Kymera
Why Kymera Therapeutics Stock Popped This Week
This week was an eventful one for Kymera Therapeutics (NASDAQ: KYMR). The clinical-stage biotech announced the early completion of enrollment in an important clinical trial. It also earned a clutch